Among adults with type 2 diabetes after COVID-19, SGLT2 inhibitor use was linked to lower recorded risk, including pain and cognitive symptoms.
Evidence
This retrospective TriNetX propensity-matched cohort compared 5,162 SGLT2 inhibitor users with 5,162 non-users diagnosed with COVID-19 from January 1, 2020, to June 30, 2024.
Caveat
Because exposure and outcomes came from observational records, the HR 0.85 association does not prove SGLT2 inhibitors prevent long COVID.
Simplified
BACKGROUND: presents significant health challenges, especially for patients with type 2 diabetes. Emerging evidence suggests that sodium-glucose cotransporter-2 (SGLT2) inhibitors may provide protective effects against COVID-19 complications, but their role in reducing long COVID risk remains unclear.
METHODS: Utilizing the TriNetX platform, a retrospective cohort study was conducted among adults with type 2 diabetes diagnosed with COVID-19 between January 1, 2020, and June 30, 2024. Propensity score matching balanced demographic, clinical, and comorbidity profiles between SGLT2 inhibitor users and non-users. Cox proportional hazards regression assessed the risk of long COVID, defined by a spectrum of post-COVID-19 conditions.
RESULTS: Among 5,162 matched pairs, SGLT2 inhibitor use was associated with a significantly lower risk of long COVID (HR = 0.85, 95% CI: 0.79-0.91). In the category of long-COVID symptoms such as abdominal symptoms, anxiety/depression, pain, headache, and cognitive symptoms, there were lower risks observed in the SGLT2 inhibitor group. Subgroup analyses showed consistent risk reduction across different age groups and sexes.
CONCLUSIONS: SGLT2 inhibitor use in patients with type 2 diabetes was linked to a reduced risk of long COVID. These findings suggest potential therapeutic benefits beyond glycemic control and highlight the need for further investigation into SGLT2 inhibitors as part of post-COVID-19 management strategies.
Key numbers
0.85
Hazard Ratio for Risk
Compared to non-users in a matched cohort of 5,162 patients.
0.76
Hazard Ratio for Younger Patients
Among patients aged 18–64 years.
0.79
Hazard Ratio for Male Patients
Compared to non-SGLT2 inhibitor users.
Full Text
We can’t show the full text here under this license.
Long Covid